NCT04580563View on ClinicalTrials.gov

Study Assessing Efficacy of Plasmatherapy in Septic Shock-induced Coagulopathy: Feasibility Study

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 22, 2020

Primary Completion Date

December 9, 2022

Study Completion Date

January 3, 2023

Conditions
Septic ShockCoagulopathyDisseminated Intravascular Coagulation
Interventions
DRUG

OctaplasLG®

Patient receive 12 ml/kg of OctaplasLG® at day 1, within the 2 hours after randomization (i.e. within the 8 hours after coagulopathy diagnosis). A new identical dose will be infused at day 2 according to coagulation parameters.

DRUG

0.9% NaCl

Patient receive 12 ml/kg of placebo (0.9% NaCl) at day 1, within the 2 hours after randomization (i.e. within the 8 hours after coagulopathy diagnosis). A new identical dose will be infused at day 2 according to coagulation parameters.

Trial Locations (1)

67000

Hôpitaux Universitaires de Strasbourg, Strasbourg

All Listed Sponsors
lead

University Hospital, Strasbourg, France

OTHER

NCT04580563 - Study Assessing Efficacy of Plasmatherapy in Septic Shock-induced Coagulopathy: Feasibility Study | Biotech Hunter | Biotech Hunter